440 related articles for article (PubMed ID: 20070992)
21. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients.
Hong SJ; Shim WJ; Choi JI; Joo HJ; Shin SY; Park SM; Lim SY; Lim DS
Am J Cardiol; 2007 Dec; 100(11):1625-9. PubMed ID: 18036359
[TBL] [Abstract][Full Text] [Related]
22. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R
Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185
[TBL] [Abstract][Full Text] [Related]
23. Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
Wang WW; Zhang FL; Chen JH; Chen XH; Fu FY; Tang MR; Chen LL
Can J Physiol Pharmacol; 2015 Aug; 93(8):657-65. PubMed ID: 26158699
[TBL] [Abstract][Full Text] [Related]
24. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.
Usui I; Fujisaka S; Yamazaki K; Takano A; Murakami S; Yamazaki Y; Urakaze M; Hachiya H; Takata M; Senda S; Iwata M; Satoh A; Sasaoka T; Ak ND; Temaru R; Kobayashi M
Diabetes Res Clin Pract; 2007 Aug; 77(2):210-4. PubMed ID: 17240472
[TBL] [Abstract][Full Text] [Related]
25. Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNFα-stimulated endothelial cells by inhibiting IKKβ expression.
Song KH; Park JH; Jo I; Park JY; Seo J; Kim SA; Cho DH
Vascul Pharmacol; 2016 Mar; 78():43-52. PubMed ID: 26455386
[TBL] [Abstract][Full Text] [Related]
26. Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Nagashima A; Watanabe R; Ogawa M; Suzuki J; Masumura M; Hishikari K; Shimizu T; Takayama K; Hirata Y; Nagai R; Isobe M
J Cardiovasc Pharmacol; 2012 Aug; 60(2):158-64. PubMed ID: 22561360
[TBL] [Abstract][Full Text] [Related]
27. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
[TBL] [Abstract][Full Text] [Related]
28. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
[TBL] [Abstract][Full Text] [Related]
29. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
30. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.
Tsukuda K; Mogi M; Iwanami J; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
Hypertension; 2009 Oct; 54(4):782-7. PubMed ID: 19635982
[TBL] [Abstract][Full Text] [Related]
31. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.
Khan AH; Imig JD
Am J Hypertens; 2011 Jul; 24(7):816-21. PubMed ID: 21415842
[TBL] [Abstract][Full Text] [Related]
32. Comparision of secretagogue effects of rosiglitazone and telmisartan on ANP secretion in rats.
Gao S; Park BM; Cha SA; Kim SZ; Kim SH
Peptides; 2014 Jun; 56():52-8. PubMed ID: 24703963
[TBL] [Abstract][Full Text] [Related]
33. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.
Aubert G; Burnier M; Dulloo A; Perregaux C; Mazzolai L; Pralong F; Zanchi A
Metabolism; 2010 Jan; 59(1):25-32. PubMed ID: 19793594
[TBL] [Abstract][Full Text] [Related]
35. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
[TBL] [Abstract][Full Text] [Related]
36. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
37. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
38. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
[TBL] [Abstract][Full Text] [Related]
39. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
Yano Y; Hoshide S; Ishikawa J; Noguchi C; Tukui D; Takanori H; Tada M; Kanemaru Y; Yano A; Ishikawa S; Shimada K; Kario K
Am J Hypertens; 2007 May; 20(5):565-72. PubMed ID: 17485023
[TBL] [Abstract][Full Text] [Related]
40. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis.
Sugimoto K; Qi NR; Kazdová L; Pravenec M; Ogihara T; Kurtz TW
Hypertension; 2006 May; 47(5):1003-9. PubMed ID: 16567593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
